First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors. (Q54499836)
Jump to navigation
Jump to search
scientific article
Language | Label | Description | Also known as |
---|---|---|---|
English | First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors. |
scientific article |
Statements
First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors. (English)
Saoirse Dolly
Maria Martinez-Garcia
Joan Albanell
Rastilav Bahleda
Federico Rojo
Emilie Routier
Ernesto Guarin
Zhi-Xin Xu
Ruediger Rueger
Jean J L Tessier
Eliezer Shochat
Steve Blotner
Valerie Meresse Naegelen
Jean-Charles Soria
3 July 2012
4806-4819